drugset / Trial / NCT03053466
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Phase 1
Completed
30 enrolled
Apollomics (Australia) Pty. Ltd.
Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.) · collabNovotech (Australia) Pty Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and recommended dose schedule of APL-501 in individuals with advanced or relapsed or recurrent solid tumors.
Timeline
- Start
- 2017-03-27
- Primary completion
- 2022-02-25
- Completion
- 2022-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APL-501 | Monoclonal antibody | 1 mg/kg | — |
| Subject | APL-501 | Monoclonal antibody | 3 mg/kg | — |
| Subject | APL-501 | Monoclonal antibody | 10 mg/kg | — |
| Subject | APL-501 | Monoclonal antibody | 400 mg | — |